Abstract:Personalized cancer immunotherapies such as therapeutic vaccines and adoptive transfer of T cell receptor (TCR)-transgenic T cells rely on the presentation of tumor-specific peptides by human leukocyte antigen (HLA) class I molecules to cytotoxic T cells. Such neoepitopes arise from somatic mutations and their identification is crucial for the rational design of new immunotherapeutic interventions. In this study, we analyzed samples of dedifferentiated liposarcoma (DDLS), which is characterized by focal amplifications on chromosome 12. Using whole exome/whole genome and RNA sequencing, we previously found that these structural changes generate open reading frames and thus presumably transcribed and translated chimeric genes. The encoded neoepitopes are promising targets for epitope-centric individualized therapies if they are presented by HLA class I molecules. Liquid chromatography mass spectrometry (LC-MS)-based immunopeptidomics is currently the only method to directly prove actual peptide presentation. We have recently developed a parameter optimization workflow to tune targeted assays for maximum detection sensitivity on a per peptide basis, termed optiPRM (optimized parallel reaction monitoring). In this study, we combined this workflow with an untargeted approach, data-independent acquisition with ion mobility separation by high-field asymmetric waveform ion mobility spectrometry (FAIMS-DIA). Using FAIMS-DIA on DDLS samples, we identified up to 16500 unique peptides per patient, including several neoepitope candidates. For the subsequent optiPRM analysis, candidate neoepitopes identified by FAIMS-DIA as well as additional candidates from variant calling with excellent predicted binding properties were synthesized as stable isotope-labeled (SIL) variant and assay-relevant parameters such as normalized collision energy (NCE) and exact retention times were determined relative to indexed retention time (iRT) peptides. Targeted analysis not only confirmed several of the FAIMS-DIA candidates but also yielded additional detections in 5 out of 6 analyzed patients. Using our complimentary FAIMS-DIA and PRM immunopeptidomics workflows, we have identified fusion-derived neoepitopes in 5 out of 8 DDLS patient samples. Importantly, the identifications contained both neoepitopes which would have been missed by the less sensitive FAIMS-DIA approach or which would have been excluded from the targeted analysis due to their poor predicted binding properties, highlighting the advantage of the combined approach. The detected neoepitopes, currently being functionally tested, represent candidates for the clinical development of personalized treatment options in liposarcoma such as cancer vaccines or TCR-based therapies. Citation Format: Jonas P Becker, Jonas D Förster, Sven Blobner, David Weber, Sebastian Uhrig, Annika Baude, Johanna Wagner, Isabel Poschke, Michael Platten, Stefan Fröhling, Peter Horak, Angelika B Riemer. Combining data-independent acquisition and targeted immunopeptidomics to enhance neoepitope discovery [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr A036.

High-Resolution Epitope Mapping for Glycosylated Antigens: Pembrolizumab-PD1 as a Case Study

Ultra-stable Biomembrane Force Probe for Accurately Determining Slow Dissociation Kinetics of PD-1 Blockade Antibodies on Single Living Cells.

Amplified visualization and function exploration of exosomal protein-specific glycosylation using hybridization chain reaction from non-functional epitope

Direct Mapping of Polyclonal Epitopes in Serum by HDX-MS

High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1

Enabling Epitope Analysis of Glycoproteins via HDX-MS Using Antigens with Uni-formed N-linked Glycans

Suppressing allostery in epitope mapping experiments using millisecond hydrogen / deuterium exchange mass spectrometry.

Quantitative High-Throughput and High-Sensitivity Glycoprofile Analysis of Therapeutic Glycoproteins Using HILIC-FLD and ESI-MS

In Situ Visualization of PD-L1-Specific Glycosylation on Tissue Sections

Residue-Specific Epitope Mapping of the PD-1/Nivolumab Interaction Using X-ray Footprinting Mass Spectrometry

Antibody binding epitope Mapping (AbMap) of two hundred antibodies in a single run

Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design

Development of a New Highly Selective Monoclonal Antibody against Preferentially Expressed Antigen in Melanoma (PRAME) and Identification of the Target Epitope by Bio-Layer Interferometry

Comprehensive Glycomic and Glycoproteomic Analyses of Human Programmed Cell Death Protein 1 Extracellular Domain

Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors

Abstract 724: MPSA-AB5000: A high-throughput membrane proteins screening array for therapeutic biologics specificity profiling

Abstract A036: Combining data-independent acquisition and targeted immunopeptidomics to enhance neoepitope discovery

Genome-wide epitope identification with single-amino-acid resolution via high-throughput and unbiased peptide analysis

Multiplexed Antibody Glycosylation Profiling Using Dual Enzyme Digestion and Liquid Chromatography-Triple Quadrupole Mass Spectrometry Method

Comprehensive N-Glycan Profiling of Cetuximab Biosimilar Candidate by NP-HPLC and MALDI-MS

Glyco-CPLL: an Integrated Method for In-Depth and Comprehensive N-Glycoproteome Profiling of Human Plasma.